Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.72
-0.0600-3.37%
Post-market: 1.730.0099+0.58%19:55 EST
Volume:1.91M
Turnover:3.33M
Market Cap:142.72M
PE:-0.60
High:1.83
Open:1.77
Low:1.67
Close:1.78
Loading ...

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
05 Nov 2024

Editas Medicine Inc : RBC Cuts Target Price to $5 From $8

THOMSON REUTERS
·
05 Nov 2024

Editas Medicine Reports Q3 2024 Results and Developments

TIPRANKS
·
05 Nov 2024

Editas Medicine Inc : Raymond James Cuts to Market Perform From Outperform

THOMSON REUTERS
·
05 Nov 2024

Press Release: ONE Gas Announces Third Quarter 2024 Financial Results; Increases 2024 Financial Guidance

Dow Jones
·
05 Nov 2024

Editas Medicine price target lowered to $5 from $8 at RBC Capital

TIPRANKS
·
05 Nov 2024

Raymond James Downgrades Editas Medicine to Market Perform From Outperform

MT Newswires Live
·
05 Nov 2024

Truist Securities Adjusts Editas Medicine's Price Target to $8 From $12, Keeps Buy Rating

MT Newswires Live
·
05 Nov 2024

Editas Medicine: Strong Cash Position and Strategic Focus on Innovative Gene Editing Programs Drive Buy Rating

TIPRANKS
·
05 Nov 2024

Editas Medicine Q3 EPS $(0.75), Inline, Sales $61.00K Miss $2.25M Estimate

Benzinga
·
05 Nov 2024

Editas Medicine downgraded to Market Perform from Outperform at Raymond James

TIPRANKS
·
05 Nov 2024

Editas Medicine Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
04 Nov 2024

BRIEF-Editas Medicine Announces Q3 Results And Business Updates

Reuters
·
04 Nov 2024

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
04 Nov 2024

Editas: Q3 Earnings Snapshot

Associated Press Finance
·
04 Nov 2024

Editas Medicine: Expects Existing Cash, Cash Equivalents, Marketable Securities to Fund Oper Expenses & Capex Into Q2 2026

THOMSON REUTERS
·
04 Nov 2024